Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-1826 combinations in NSCLC
NCT06754930Phase 2Recruiting
- Sponsor
- Suzhou Suncadia Biopharmaceutical
- Start
- Feb 2025
- Primary completion
- Dec 2027
- Modality
- Small Molecules, Antibody-Drug Conjugates (ADCs), Engineered Antibody Formats
- Countries
- 1
01
Overview
A Phase 2 trial of SHR-1826 in non-small cell lung cancer (NSCLC), sponsored by Suzhou Suncadia Biopharmaceutical. Started Feb 2025; status: recruiting.
02
Drugs
SHR-1826
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06754930.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06754930.